Enliven Therapeutics Files 8-K on Director/Officer Changes
Ticker: ELVN · Form: 8-K · Filed: Apr 9, 2024 · CIK: 1672619
| Field | Detail |
|---|---|
| Company | Enliven Therapeutics, Inc. (ELVN) |
| Form Type | 8-K |
| Filed Date | Apr 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $35,000, $500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
TL;DR
Enliven Therapeutics (formerly IMARA) filed an 8-K detailing board and officer changes.
AI Summary
Enliven Therapeutics, Inc. filed an 8-K on April 9, 2024, reporting changes related to its board of directors and officers, as well as compensatory arrangements. The filing also includes financial statements and exhibits. The company, formerly known as IMARA Inc., is incorporated in Delaware and based in Boulder, Colorado.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing is primarily procedural, reporting changes in directors and officers, and does not contain significant financial or operational news.
Key Players & Entities
- Enliven Therapeutics, Inc. (company) — Registrant
- IMARA Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Boulder, Colorado (location) — Principal executive offices
- April 8, 2024 (date) — Date of earliest event reported
- April 9, 2024 (date) — Date of report
FAQ
What specific changes were made regarding directors or officers?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers', but the specific details of these changes are not provided in the provided text.
What is the former name of Enliven Therapeutics, Inc.?
The former name of Enliven Therapeutics, Inc. was IMARA Inc.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on April 8, 2024.
Where are Enliven Therapeutics, Inc.'s principal executive offices located?
Enliven Therapeutics, Inc.'s principal executive offices are located at 6200 Lookout Road, Boulder, Colorado, 80301.
What is the SIC code for Enliven Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Enliven Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 645 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2024-04-09 16:14:01
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ELVN The Nasdaq Global Se
- $35,000 — his includes an annual cash retainer of $35,000 per year for service as an outside dire
- $500,000 — nting principles equal to approximately $500,000. These stock options vest as to 1/36th
Filing Documents
- d816494d8k.htm (8-K) — 27KB
- d816494dex991.htm (EX-99.1) — 5KB
- g816494g0409024325657.jpg (GRAPHIC) — 4KB
- 0001193125-24-090821.txt ( ) — 161KB
- elvn-20240408.xsd (EX-101.SCH) — 3KB
- elvn-20240408_lab.xml (EX-101.LAB) — 18KB
- elvn-20240408_pre.xml (EX-101.PRE) — 11KB
- d816494d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press release dated April 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Enliven Therapeutics, Inc. Date: April 9, 2024 By: /s/ Samuel Kintz Name: Samuel Kintz Title: President and Chief Executive Officer